These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 17102189)

  • 1. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(6):1637-47. PubMed ID: 17102189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.
    Kelton CM; Chang LV; Kreling DH
    Health Aff (Millwood); 2013 Jul; 32(7):1204-11. PubMed ID: 23836735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
    Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
    Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
    Seay M; Varma P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.
    Fischer MA; Avorn J
    Health Serv Res; 2003 Aug; 38(4):1051-63. PubMed ID: 12968816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
    [No Abstract]   [Full Text] [Related]  

  • 12. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceuticals and medical devices: cost savings.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicaid cost containment and access to prescription drugs.
    Cunningham PJ
    Health Aff (Millwood); 2005; 24(3):780-9. PubMed ID: 15886173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
    Boulet AP; Tessier G
    Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.
    Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
    Ann Pharmacother; 2012 Apr; 46(4):503-12. PubMed ID: 22454448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copayment coupons undermine formularies.
    Manag Care; 2011 Dec; 20(12):63. PubMed ID: 22259878
    [No Abstract]   [Full Text] [Related]  

  • 20. Prior authorization for Medicaid drugs.
    Iowa Med; 1995 Aug; 85(8):319. PubMed ID: 7558744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.